Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SHE:300357)
27.76
+0.28 (1.02%)
Feb 3, 2026, 3:04 PM CST
SHE:300357 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 1,055 | 1,119 | 1,171 | 840.69 | 649.99 | 583.68 |
Trading Asset Securities | 286.82 | 196.09 | 117.39 | 295.05 | 370.93 | 307.03 |
Cash & Short-Term Investments | 1,342 | 1,315 | 1,289 | 1,136 | 1,021 | 890.71 |
Cash Growth | 7.22% | 2.03% | 13.47% | 11.25% | 14.62% | 12.44% |
Accounts Receivable | 346.17 | 251.04 | 202.92 | 254.31 | 238.12 | 206.77 |
Other Receivables | 6.2 | - | - | 19.81 | 11.13 | 8.57 |
Receivables | 352.38 | 251.04 | 202.92 | 274.12 | 249.26 | 215.35 |
Inventory | 53.7 | 57.73 | 59.04 | 48.41 | 53.75 | 48.33 |
Other Current Assets | 24.3 | 27.78 | 19.17 | 18.86 | 17.58 | 16.55 |
Total Current Assets | 1,772 | 1,651 | 1,570 | 1,477 | 1,342 | 1,171 |
Property, Plant & Equipment | 852.98 | 780.09 | 704.84 | 444.61 | 301.62 | 240.16 |
Long-Term Investments | 77.26 | 77.94 | 74.21 | 78.4 | 83.35 | 13.86 |
Other Intangible Assets | 151.86 | 162.79 | 161.38 | 139.67 | 94 | 61.01 |
Long-Term Deferred Tax Assets | 6.78 | 5.6 | 5.03 | 4.87 | 5.81 | 4.9 |
Long-Term Deferred Charges | 28.42 | 25.27 | 34.38 | 53.2 | 86.05 | 113.89 |
Other Long-Term Assets | 3.6 | 5.94 | 12.42 | - | 19.63 | - |
Total Assets | 2,893 | 2,709 | 2,562 | 2,198 | 1,932 | 1,605 |
Accounts Payable | 36.03 | 47.77 | 7.99 | 7.68 | 5.08 | 5.66 |
Accrued Expenses | 26.99 | 35.13 | 33.57 | 29.89 | 35.54 | 23.15 |
Short-Term Debt | 5 | 12.63 | 34.39 | - | - | - |
Current Portion of Leases | 4.68 | 5.03 | 6.8 | 3.98 | 5.86 | - |
Current Income Taxes Payable | 33.51 | 10.56 | 9.26 | 26.08 | 50.32 | 9.59 |
Current Unearned Revenue | 0.63 | 0.51 | 0.38 | 0.42 | 0.42 | 0.44 |
Other Current Liabilities | 13.1 | 70.95 | 84.64 | 34.71 | 10.78 | 16.57 |
Total Current Liabilities | 119.95 | 182.58 | 177.04 | 102.75 | 108 | 55.42 |
Long-Term Leases | 9.72 | 7.93 | 21.26 | 12.28 | 1.95 | - |
Long-Term Unearned Revenue | 32.22 | 33.53 | 30.93 | 27.43 | 24.91 | 20.63 |
Long-Term Deferred Tax Liabilities | 0.09 | 0.17 | 0.2 | 0.08 | 0.5 | 0.56 |
Other Long-Term Liabilities | - | 26.08 | 29.03 | 28.22 | - | - |
Total Liabilities | 161.98 | 250.3 | 258.46 | 170.76 | 135.36 | 76.61 |
Common Stock | 523.58 | 523.58 | 523.58 | 523.58 | 523.58 | 523.58 |
Additional Paid-In Capital | 128.19 | 128.19 | 128.19 | 128.19 | 128.19 | 128.19 |
Retained Earnings | 1,984 | 1,702 | 1,533 | 1,328 | 1,084 | 803.26 |
Comprehensive Income & Other | 0.03 | 0.04 | 0.03 | 0.03 | 0 | 0.87 |
Total Common Equity | 2,636 | 2,354 | 2,185 | 1,980 | 1,736 | 1,456 |
Minority Interest | 95.49 | 105.12 | 118.61 | 47.49 | 60.54 | 72.24 |
Shareholders' Equity | 2,731 | 2,459 | 2,304 | 2,027 | 1,797 | 1,528 |
Total Liabilities & Equity | 2,893 | 2,709 | 2,562 | 2,198 | 1,932 | 1,605 |
Total Debt | 19.39 | 25.59 | 62.44 | 16.26 | 7.81 | - |
Net Cash (Debt) | 1,323 | 1,289 | 1,226 | 1,119 | 1,013 | 890.71 |
Net Cash Growth | 10.13% | 5.14% | 9.54% | 10.50% | 13.74% | 12.44% |
Net Cash Per Share | 2.53 | 2.46 | 2.34 | 2.14 | 1.93 | 1.70 |
Filing Date Shares Outstanding | 523.58 | 523.58 | 523.58 | 523.58 | 523.58 | 523.58 |
Total Common Shares Outstanding | 523.58 | 523.58 | 523.58 | 523.58 | 523.58 | 523.58 |
Working Capital | 1,652 | 1,469 | 1,393 | 1,374 | 1,234 | 1,116 |
Book Value Per Share | 5.03 | 4.50 | 4.17 | 3.78 | 3.32 | 2.78 |
Tangible Book Value | 2,484 | 2,191 | 2,024 | 1,840 | 1,642 | 1,395 |
Tangible Book Value Per Share | 4.74 | 4.18 | 3.87 | 3.51 | 3.14 | 2.66 |
Buildings | - | 428.52 | 423.31 | 175.67 | 137.89 | 137.89 |
Machinery | - | 135.42 | 115.99 | 95.51 | 77.11 | 71.89 |
Construction In Progress | - | 323.16 | 227.86 | 226.24 | 140.33 | 80.46 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.